Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters

Contraception

Volumn 63, Issue 3, 2001, Pages 151-153

  Bulent Tiras, M ^a   Noyan, Volkan ^b   Fener, Nesrin ^a   Guner, Haldun ^a   Yildirim, Mulazim ^a   Darney, Philip D ^c  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c University of California at Santa Cruz   (United States)

Author keywords

Coagulation system; Lipid profile; Menstrual pattern; Mesigyna; Monthly injectable contraception

Indexed keywords

ALBUMIN; BILIRUBIN; CHOLESTEROL; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; INJECTABLE CONTRACEPTIVE AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTHROMBIN; STEROID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CONTRACEPTION; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERMENORRHEA; LIPID BLOOD LEVEL; LIVER FUNCTION; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISORDER; METRORRHAGIA; NORMAL HUMAN; PROTHROMBIN TIME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035013307     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00190-1     Document Type: Article

References (13)

1. UNDP/UNFPA/WHO/WB. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism. Contraception 1997;56:193–207
2. G. Benagiano F.M. Primiero Long-acting steroid contraceptives, present status Drugs 25 1983 570 609
3. G.W. Sang Q.X. Shao R.S. Ge J.K. Chen A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem, and Injectable No.1 given monthly by i.m. injection to Chinese women Contraception 51 1995 167 183
4. E. Kesseru A multicentered two-year phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive Contraception 49 1991 421 433
5. E. Kesseru Multicentered phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report Contraception 50 1994 329 337
6. WHO/TFLSAFR/SPR/DRTHR. A multicentered phase III comparative study of two hormonal contraceptive preparations given once-a-month by i.m. injection. II. The comparison of bleeding patterns. Contraception 1989;40:531–51
7. N.A. Haiba M.A. El-Habashy S.A. Said E.A. Darwish W.S. Abdel-Sayed S.E. Nayel Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters Contraception 39 1989 619 631
8. C.R. Kay The Royal College of General Practitioners oral contraception study some recent observations Clin Obstet Gynecol 11 1984 759 786
9. G. Benagiano F.M. Primiero C. Bastianelli P. Bianchi E. Medda Comparative clinical evaluation of the effect on carbohydrate and lipid metabolism of two norethisterone-containing hormonal contraceptives Mesigyna and TriNovum Contraception 55 1997 295 300
10. E. Kesseru H. Albornoz M. Diaz R. Socolsky Serum lipid variations in women on copper intrauterine devices, triphasic oral contraceptives and monthly injectable contraceptives Contraception 44 1991 235 244
11. Giwa-Osagie F, and the WHO Task Force on Long-Acting Systemic Agents for Fertility Regulation. Metabolic effects of once-a-month combined injectable contraceptives. Contraception l994;49:421–33
12. Y.X. Meng H.Y. Jiang F.Y. Lu The effects of long-term use of once-a-month injectable contraceptive norethisterone enanthate/estradiol valerate on coagulation on the Chinese Thromb Haemost 64 1990 548 549
13. UNDP/UPF/WHO/WB/SPR/DRTHR. Task Force on Long-acting Systemic Agents for Fertility Regulation. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on glucose metabolism and liver function. Contraception 1998;57:71–81.